Podcasts about 3C

《360°生活家》－全面升級你的日常！ 想一次掌握生活資訊、科技新知、3C智慧與健康趨勢嗎？ 《360°生活家》每集帶你從不同角度探索生活的無限可能 無論是科技新品開箱、健康生活技巧，還是日常小撇步 都能讓你輕鬆成為生活達人，開啟更有品質的精彩人生！ 現在就跟著我們，360度全面升級你的生活吧！ 歡迎訂閱、收聽，每日更新精彩內容 陪你一起輕鬆享受智慧、健康、便利的美好生活！

《360°生活家》－全面升級你的日常！ 想一次掌握生活資訊、科技新知、3C智慧與健康趨勢嗎？ 《360°生活家》每集帶你從不同角度探索生活的無限可能 無論是科技新品開箱、健康生活技巧，還是日常小撇步 都能讓你輕鬆成為生活達人，開啟更有品質的精彩人生！ 現在就跟著我們，360度全面升級你的生活吧！ 歡迎訂閱、收聽，每日更新精彩內容 陪你一起輕鬆享受智慧、健康、便利的美好生活！

《360°生活家》－全面升級你的日常！ 想一次掌握生活資訊、科技新知、3C智慧與健康趨勢嗎？ 《360°生活家》每集帶你從不同角度探索生活的無限可能 無論是科技新品開箱、健康生活技巧，還是日常小撇步 都能讓你輕鬆成為生活達人，開啟更有品質的精彩人生！ 現在就跟著我們，360度全面升級你的生活吧！ 歡迎訂閱、收聽，每日更新精彩內容 陪你一起輕鬆享受智慧、健康、便利的美好生活！

《360°生活家》－全面升級你的日常！ 想一次掌握生活資訊、科技新知、3C智慧與健康趨勢嗎？ 《360°生活家》每集帶你從不同角度探索生活的無限可能 無論是科技新品開箱、健康生活技巧，還是日常小撇步 都能讓你輕鬆成為生活達人，開啟更有品質的精彩人生！ 現在就跟著我們，360度全面升級你的生活吧！ 歡迎訂閱、收聽，每日更新精彩內容 陪你一起輕鬆享受智慧、健康、便利的美好生活！

欢迎收听雪球出品的财经有深度，雪球，国内领先的集投资交流交易一体的综合财富管理平台，聪明的投资者都在这里。今天分享的内容叫美团阿里开始豪赌未来，来自王智远同学。7月5号，阿里淘宝闪购突然发起一场名为“淮海战役”的补贴大战，目标很明确：每周六集中火力冲单量。阿里为什么要主动发起这样一场战役？战略意图是什么？01我觉得，阿里真正想赢的，是淘宝未来。为什么这么说？因为淘宝这套传统货架模式的增长已经接近天花板，年增长率不到10%，明显放缓；而另一边，即时零售——也就是外卖+快消品——仍在以超过20%的速度增长。这说明，人们越来越习惯“马上要、立刻有”的消费方式。阿里在思考：如果我能把用户从“一个月逛几次淘宝”，变成“一周点好几单外卖”，那不就等于给淘宝装上了一个新的发动机？而且，这个发动机很猛。外卖是高频行为，每天都要吃饭、喝咖啡、买零食。一旦用户习惯了通过淘宝闪购点外卖，就会开始顺手买点别的东西。比如：7月5日当天，淘宝闪购的粮油、母婴、家电等品类订单同比增长超100%。用户开始像“双11囤货”一样，囤起了即时消费品。再来看一组数据：截至7月5日22时54分，淘宝闪购非餐饮类订单已达1300万单，相比一年前翻了6倍；美团同期也有约2000万单是非餐饮交易。这说明，两个平台都在试图用外卖带动零售，谁先养成就用户习惯，谁就能赢得主动权。阿里还有一个别人难以复制的优势：流量太大。QuestMobile数据显示，2025年1至5月，淘宝App日活用户增长至4.1亿，美团外卖日均支付订单维持在9000万以上。7月5日那天阿里直接将所有App开屏广告全换成橙色促销，一下触达了几亿人；这种打法，美团根本接不住。更狠的是，阿里还把饿了么和支付宝深度绑定。你点个外卖，顺便就把支付宝用了；如果你是88VIP会员，还能直接送你一个饿了么会员。这种生态联动，让整个消费路径变得更顺畅，也更容易留住用户。当然，美团也不是没有反击能力。它同样能靠补贴冲单量，1亿单的规模随时可以做到；但问题在于，美团不像阿里那样拥有庞大的流量池，也没有那么多可补的零售品类支撑这场战争。还有一个关键时间窗口，阿里必须抢在前面出手。因为美团也在悄悄打造自己的“零售版淘宝”，它的闪购业务已占GMV的15%，涵盖超市、便利、数码家电等多个品类。换句话说，它不只是要做外卖，还想做更多。但目前，它的商品丰富度尚未完全上来，尤其在生鲜、母婴等高毛利品类上。这时，阿里突然出手，就像在美团盖楼之前，先把脚下的地基给挖松了。如果你仔细看淘宝闪购公布的数据，会发现一个有意思的细节：粮油米面、冷冻食品、家清、母婴、个护等品类的订单增速最快。这说明，阿里正在借助外卖打开用户的生活圈，所以回过头看这场战役，智远主观分析认为，阿里的战略目的有三：一，改造淘宝，用外卖的高频需求激活用户活跃度；二，拖住美团，逼它在补贴战中持续消耗现金流；三，抢占心智，让“30分钟送达”成为淘宝的新标签。换句话说，阿里想借外卖的风，把淘宝吹向一个新阶段。02不过，美团也不是没有反击能力。它只用12个小时，就把订单量从日常的9000万单提升到1.2亿单，直接冲上历史峰值。这波操作可以说是“闪电反击”，也再次展示了美团在外卖战场上的硬实力，它靠一套真刀真枪打磨出来的配送系统。它手里握着全国最大的即时配送网络，700万骑手中，日均活跃的有336万，占整个中国即时配送市场的60%以上。换句话说，全国每10个送外卖的人里，就有6个是美团的。除了自有运力，它还有麦芽田和青云两大聚合平台，这两个系统可以整合大量第三方配送公司，单日最高调度能力超过1000万单。更关键的是，它的动态定价机制。高峰期时，骑手每单奖励能飙到10元，但美团仍基本保证了餐品按时送达。听起来是不是很稳？但这场比赛也暴露了一个问题：系统虽然强大，也有自己的天花板。比如，7月5日晚高峰时，订单突然暴涨，导致美团旗下麦芽田服务器一度崩溃，部分订单延迟了1到2小时；这种事在日常可能还能扛得住，但在极限对战中，就容易出问题。而且别忘了，光为了维持这个系统的运转，美团每天就要烧掉两亿多的补贴成本。你说这能撑多久？再来看另一个角度：美团在非餐饮品类布局远超竞对。它有自己的前置仓体系，加上3万多加盟闪电仓，在北京望京区域，三公里范围内就能覆盖20万个SKU，而传统超市如沃尔玛，通常只有3万个左右。什么概念？它真的能做到“你要什么我都能送”，但背后的问题也很明显：模式太重，利润太薄。美团2024年全年经营利润为368亿元，其中外卖贡献约325亿元；但今年的补贴支出将在去年基础上新增至少100亿元，如果下半年竞争加剧，还可能增加150亿到200亿元。同时，美团闪购是重资产路线，毛利率仅为20%-25%，客单价65元，履约成本却高达8元，虽然这一差距相比外卖业务正在缩小，但整体压力依然不小。再加上3万多家加盟闪电仓和自营前置仓，每天的维护成本都超过千万。相比之下，阿里那500亿补贴分摊到12个月，平均每天不到1.4亿，和美团日常营销支出已相当接近。这就像一场耐力赛，看谁更能耗。最危险的信号出现在哪里？是美团开始发放“用户自提免单券”，这是它在用一种损害用户体验的方式去止损。已有用户反馈说“缺货”或“覆盖范围有限”，说明这套模式仍在探索阶段。你看，运力已经快到极限了，但它还不能停。所以回过头看这场“1.2亿单反击战”，你会发现：美团的护城河确实很深，短期内没人能轻易撼动；但它维护这座护城河的成本太高，就像一边建城墙，一边还要不停往里面灌水泥；它现在面对一个带着生态打法来的超级平台。03这场仗打得越狠，就越有人在替平台“买单”，真正承受代价的，还有商家、骑手，甚至整个行业的生态平衡。智远了解到，不少连锁品牌接到通知时已经是下午：“今天要冲单量，你们得配合。”听起来像是临时加戏，但对商家来说，这是一场突如其来的“硬仗”。人力成本飙升，他们不得不临时高薪请人打包，甚至找兼职帮忙。如果真爆单了还好，一旦没爆单，牛奶、水果等原料只能白白浪费。再来看平台这边。以美团1.2亿单为例：每天光是直接补贴就得花掉12亿元，还有大量隐性支出——服务器扩容、投诉赔偿、骑手保险……这些账单藏在后台，没人看见，却一样都不能少。换句话说，这是一次对整个运营系统的极限测试。再看一个容易被忽略的群体：小商户和区域品牌。在这场战斗中，受益最多的还是头部连锁品牌。像一些大型连锁奶茶店，接到通知后能立刻调动IT团队做系统调整，临时加派人手打包出餐，还能与平台谈判争取配送保底。他们不仅接得住这波流量，打完仗之后还可能获得平台的流量倾斜。可小商户呢？很多人连消息都没接到就被卷进去了。有的直到订单突然暴涨才发现系统根本扛不住，配送费涨了不敢拒绝，抽成也比平时高了不少，但又不得不接。最惨的是，因为履约慢，平台还可能降权，下一轮流量红利就彻底没他们的份了；所以，这场仗表面上是平台在烧钱，实际上压力最大的，是那些没有议价能力的小玩家。当然，也不能忘记消费者。“0元奶茶”让你高频打开App，提升日活；你授权了地理位置权限，平台借此掌握你的消费轨迹；你还慢慢接受了动态定价机制，一杯奶茶涨价几块钱，也开始觉得“好像也没那么离谱”。我自己就有体会：第一天喝肯悦咖啡才4块多，第二天涨到了6块多，到现在几乎恢复原价了。我还特意问了一个不太常点外卖的朋友，他的日常价也才6块多。所以，看似微不足道的变化，在悄悄改写你的消费习惯。而且历史经验告诉我们，低价红利一旦结束，用户流失速度也快得惊人；还记得网约车大战吗？当时订单量暴涨，但补贴一停，用户留存率不到很低。虽然我没有明确数据，说明外卖大战用户留存情况，但一个大家都默认的事实是：平台砸钱换来的增长，往往只是短暂的幻觉。因此，表面上看，这是阿里和美团之间的一场补贴大战；实际上，真正承受代价的，是商家、骑手、消费者，甚至是整个行业的生态平衡。04那么，这场“淮海战役”打到最后，即时零售行业会迎来新大陆吗？短期来看，未来6到12个月是一场拉锯战。阿里的打法很明确，每周末都来一次“7月5日”的翻版，目标是让“超级星期六”变成用户的生活习惯。听起来很美好，但也有风险：用户会不会慢慢疲了？淘宝流量转化率会不会递减？非餐饮品类如生鲜、母婴，履约成本更高，阿里能不能扛得住？美团当然不会坐以待毙。被迫跟进补贴，会不会玩得更精细，比如：在阿里重点城市上线“神枪手”低价专区；用闪电仓密集覆盖高潜力社区，降低最后一公里配送成本？所以，智远认为，双方现在就像两个赌徒，赌谁先停。中期来看，谁先撑不住，谁就出局，到了这个阶段，拼的就是谁能活得更久。这里有三个绕不过去的坎儿：第一个是毛利率陷阱。外卖业务本身毛利还能做到30%左右，但一旦涉及生鲜、冷链这些品类，毛利率直接掉到15%-20%，甚至更低。第二个是运力成本刚性，骑手每单的成本从原来的6-8元涨到了10-12元，而消费者实付却从9-11元降到了0-3元。这不是做生意。第三个是资本耐心见底，美团股价已经比高峰时跌了60%多，市场对亏损的容忍度越来越低；阿里虽然现金流充足，但电商主业也在承压，不可能无限输血。还有一个关键临界点：当单日订单常态化突破1.5亿单时，每增加1000万单，可能就意味着每天多亏2亿元，这已经不是增长，而是出血。那未来的终局是什么样？智远觉得有几个可能性：第一种：垂直分化，美团继续主导餐饮加便利店这类高频需求，阿里掌控生鲜、母婴等高毛利品类；京东聚焦3C数码等高客单价即时配送。第二种：资本合并，美团和阿里成立合资公司，各自划分区域运营；前提是反垄断政策松动，但现在看概率非常低。第三种就是生态重构了，黑天鹅事件，即时零售和社区团购融合，或者无人配送技术突破，直接降低60%的运力成本。所以，即时零售既是绞肉机，也是新大陆，只不过，要先流血，才能看到绿洲。短期内，阿里需要一场“斯大林格勒战役”式的胜利，美团则要避免被拖入消耗战；中期内，谁现金流更稳，谁就能活得更久。目前来看，阿里 账上6137 亿元，美团大概 2000 亿元储备，差距明显；长期来看，30分钟送达将成为像水电煤一样的基础设施，但赢家可能不超过两家。如果拼多多再进来呢？所以，别看现在打得热闹，真正的淘汰赛，才刚刚开始；也许再过一年，当我们站在新起点回看这一切时会发现：如今这场混战，不过是通往未来的第一站。

《360°生活家》－全面升級你的日常！ 想一次掌握生活資訊、科技新知、3C智慧與健康趨勢嗎？ 《360°生活家》每集帶你從不同角度探索生活的無限可能 無論是科技新品開箱、健康生活技巧，還是日常小撇步 都能讓你輕鬆成為生活達人，開啟更有品質的精彩人生！ 現在就跟著我們，360度全面升級你的生活吧！ 歡迎訂閱、收聽，每日更新精彩內容 陪你一起輕鬆享受智慧、健康、便利的美好生活！

《360°生活家》－全面升級你的日常！ 想一次掌握生活資訊、科技新知、3C智慧與健康趨勢嗎？ 《360°生活家》每集帶你從不同角度探索生活的無限可能 無論是科技新品開箱、健康生活技巧，還是日常小撇步 都能讓你輕鬆成為生活達人，開啟更有品質的精彩人生！ 現在就跟著我們，360度全面升級你的生活吧！ 歡迎訂閱、收聽，每日更新精彩內容 陪你一起輕鬆享受智慧、健康、便利的美好生活！

Potencia tu Inteligencia Emocional y tu Productividad con Efrén Martínez En este episodio de Mente Sana Tips, converso con Efrén Martínez, psicólogo, investigador y experto en salud mental y liderazgo, sobre temas que pueden transformar tu forma de vivir y liderar: 💡 ¿Qué aprenderás hoy? ✔️ Cómo la inteligencia emocional es tu mayor estrategia de productividad ✔️ Por qué la salud mental es un activo estratégico para líderes y profesionales ✔️ Las 3C para una vida resiliente: Compromiso, Control y Cambio 🔎 Sobre este episodio: Descubre herramientas prácticas y reflexiones profundas para liderarte mejor, cuidar tu mente y potenciar tu desempeño sin sacrificar tu bienestar. ✨ Recuerda: No hay productividad sin salud mental. No hay liderazgo sin inteligencia emocional. 📝 Cuéntame en comentarios: ¿Cuál de las 3C necesitas fortalecer hoy para vivir con más propósito y resiliencia?

[00:00] The End of the Core Four [10:25] Marner's legacy and perception in Toronto going forward [26:10] The devastating loss of Pontus Holmberg [34:44] John Tavares signs a team-friendly deal [41:35] Matthew Knies becomes a core player [48:38] Evaluating Steven Lorentz and fourth-line strategy [52:03] The Leafs take a flier on Matias Maccelli [1:03:20] Treliving finds a legit 3C in Nicolas Roy [1:09:27] Some depth contracts + team overview

Dr.Judy Bauer shares the 3C's and how you can apply these attributes to ensure you get the most out of life every day. Visit http://www.epicwin4u.com for links and show notes and join in on the conversation @EpicConqerors on Facebook. If you enjoy our bi-weekly podcasts and videocasts then simply buy us a coffee: https://www.buymeacoffee.com/KingJesus

《360°生活家》－全面升級你的日常！ 想一次掌握生活資訊、科技新知、3C智慧與健康趨勢嗎？ 《360°生活家》每集帶你從不同角度探索生活的無限可能 無論是科技新品開箱、健康生活技巧，還是日常小撇步 都能讓你輕鬆成為生活達人，開啟更有品質的精彩人生！ 現在就跟著我們，360度全面升級你的生活吧！ 歡迎訂閱、收聽，每日更新精彩內容 陪你一起輕鬆享受智慧、健康、便利的美好生活！

一项关于携带充电宝登机的新规定让很多旅客猝不及防。中国民航局宣布，禁止旅客携带没有3C标识的充电宝乘坐境内航班，自上周六（6月28日）起生效。什么是3C标识？为何禁止携带没有3C标识的充电宝登机？点击 ▶ 收听完整采访。

最貼近大眾的軍事節目《國防在線急》上線囉

China's aviation regulator has banned uncertified power banks on domestic flights, citing urgent safety concerns over fires and other hazards linked to lithium batteries, State media reported on Wednesday.据官方媒体周三报道，中国航空监管机构以对锂电池相关火灾和其他危险的紧急安全担忧为由，禁止未经认证的充电宝乘坐国内航班。The Civil Aviation Administration of China told People's Daily that quality issues with lithium batteries in power banks have threatened aviation safety, prompting the move. The ban, which took effect on Saturday, applies to power banks without valid China Compulsory Certification — known as 3C — those with unclear 3C labels or those subject to product recalls.中国民用航空局告诉《人民日报》，移动电源锂电池的质量问题已经威胁到航空安全，促使采取了这一行动。该禁令于周六生效，适用于没有有效的中国强制认证（即3C）的电力银行，即3C标签不清楚或产品被召回的电力银行。The 3C certification is a mandatory safety and quality standard for products sold in China. For power banks, it ensures they do not pose risks of fire, electric shock or other hazards. The country began 3C certification for power banks on Aug 1, 2023, and sales of products without the certification have been prohibited since Aug 1 last year.3C认证是在中国销售的产品的强制性安全和质量标准。对于移动电源，它确保它们不会造成火灾、触电或其他危险。该国于2023年8月1日开始对移动电源进行3C认证，自去年8月1日起禁止销售未经认证的产品。The administration said the measure follows a surge in incidents globally involving fires and smoke from lithium batteries on aircraft, including 15 cases in China's aviation sector this year. In one incident on Jan 28, a fire broke out on an Air Busan flight due to a passenger's power bank, damaging the aircraft.美国政府表示，该措施是在全球范围内涉及飞机锂电池火灾和烟雾的事件激增之后采取的，其中包括今年中国航空业的15起案件。在1月28日的一起事件中，釜山航空的一架航班因一名乘客的移动电源发生火灾，导致飞机受损。Lithium batteries are prone to risks under external factors such as high temperatures, pressure and collisions, which can lead to internal short circuits and excessive heat. This can trigger thermal runaway in the battery, resulting in fires or explosions that are difficult to extinguish, the regulator said.美国政府表示，该措施是在全球范围内涉及飞机锂电池火灾和烟雾的事件激增之后采取的，其中包括今年中国航空业的15起案件。在1月28日的一起事件中，釜山航空的一架航班因一名乘客的移动电源发生火灾，导致飞机受损。A recent report from China's market regulation authority found that out of 149 batches of power banks inspected, 65 were substandard, the administration noted.政府指出，中国市场监管机构最近的一份报告发现，在检查的149批电力银行中，有65批不合格。A staff member at Beijing Capital International Airport told China Daily that passengers carrying power banks must now show 3C marks at security checks, and devices under recall will not be allowed through. Power banks under 100 watt-hours can be carried onboard, while those between 100 and 160 watt-hours require airline approval. Devices exceeding 160 watt-hours are prohibited.北京首都国际机场的一名工作人员告诉《中国日报》，携带电动银行的乘客现在必须在安检时出示3C标志，被召回的设备将不允许通过。100瓦时以下的移动电源可以携带登机，而100至160瓦时之间的移动电源需要航空公司的批准。禁止使用超过160瓦时的设备。Noncompliant power banks found during checks will be handled according to passengers' preferences, the administration said. Airports will provide areas for passengers to abandon or temporarily store their devices, along with mailing services for those who wish to send them home.政府表示，在检查过程中发现的不合规移动电源将根据乘客的喜好进行处理。机场将为乘客提供丢弃或临时存放设备的区域，并为希望将设备送回家的乘客提供邮寄服务。Power banks abandoned or left beyond storage deadlines will be destroyed or recycled after consultation with battery recovery companies, the administration said. Records will be maintained throughout storage, transfer and recycling to ensure traceability and prevent unauthorized devices from reentering the market.政府表示，在与电池回收公司协商后，废弃或超过储存期限的移动电源将被销毁或回收。记录将在整个储存、转移和回收过程中得到维护，以确保可追溯性，防止未经授权的设备重新进入市场。lithium batteriesn.锂电池traceabilityn.可追溯性

《360°生活家》－全面升級你的日常！ 想一次掌握生活資訊、科技新知、3C智慧與健康趨勢嗎？ 《360°生活家》每集帶你從不同角度探索生活的無限可能 無論是科技新品開箱、健康生活技巧，還是日常小撇步 都能讓你輕鬆成為生活達人，開啟更有品質的精彩人生！ 現在就跟著我們，360度全面升級你的生活吧！ 歡迎訂閱、收聽，每日更新精彩內容 陪你一起輕鬆享受智慧、健康、便利的美好生活！

《360°生活家》－全面升級你的日常！ 想一次掌握生活資訊、科技新知、3C智慧與健康趨勢嗎？ 《360°生活家》每集帶你從不同角度探索生活的無限可能 無論是科技新品開箱、健康生活技巧，還是日常小撇步 都能讓你輕鬆成為生活達人，開啟更有品質的精彩人生！ 現在就跟著我們，360度全面升級你的生活吧！ 歡迎訂閱、收聽，每日更新精彩內容 陪你一起輕鬆享受智慧、健康、便利的美好生活！

《360°生活家》－全面升級你的日常！ 想一次掌握生活資訊、科技新知、3C智慧與健康趨勢嗎？ 《360°生活家》每集帶你從不同角度探索生活的無限可能 無論是科技新品開箱、健康生活技巧，還是日常小撇步 都能讓你輕鬆成為生活達人，開啟更有品質的精彩人生！ 現在就跟著我們，360度全面升級你的生活吧！ 歡迎訂閱、收聽，每日更新精彩內容 陪你一起輕鬆享受智慧、健康、便利的美好生活！

《360°生活家》－全面升級你的日常！ 想一次掌握生活資訊、科技新知、3C智慧與健康趨勢嗎？ 《360°生活家》每集帶你從不同角度探索生活的無限可能 無論是科技新品開箱、健康生活技巧，還是日常小撇步 都能讓你輕鬆成為生活達人，開啟更有品質的精彩人生！ 現在就跟著我們，360度全面升級你的生活吧！ 歡迎訂閱、收聽，每日更新精彩內容 陪你一起輕鬆享受智慧、健康、便利的美好生活！

VOV1 - Sáng 28/6, tại Trụ sở Chính phủ, Thủ tướng Phạm Minh Chính toạ đàm với các doanh nghiệp Vương quốc Anh đang đầu tư tại Việt Nam.- Thủ tướng Phạm Minh Chính chủ trì Tọa đàm với các doanh nghiệp của Vương quốc Anh đang đầu tư tại Việt Nam.- Bí thư Đảng ủy Quốc hội, Chủ tịch Quốc hội Trần Thanh Mẫn dự và chỉ đạo tại Đại hội Đảng bộ Ủy ban Pháp luật và Tư pháp.-Bộ Nội vụ ban hành 'Cẩm nang chính quyền địa phương cấp xã', một tài liệu quan trọng phục vụ công tác đào tạo, bồi dưỡng, hướng dẫn chuyên môn nghiệp vụ cho cán bộ, công chức cấp xã.- Các tỉnh Bắc bộ chủ đọng ứng phó với mưa lớn.- Cả Mỹ và Israel cảnh báo đều có kế hoạch đối phó nhằm vào Iran nếu quốc gia hồi giáo vẫn làm giàu urani đến mức đáng lo ngại.-Trung Quốc cấm mang sạc dự phòng không có nhãn 3C lên máy bay.

VOV1 - Từ hôm nay 28/6, Cục Hàng không Dân dụng Trung Quốc đã chính thức áp dụng quy định mới, cấm hành khách mang theo sạc dự phòng nếu sản phẩm không có nhãn “3C” – một chứng nhận sản phẩm bắt buộc của Trung Quốc - hoặc nhãn mờ, hay thuộc lô đã bị thu hồi, khi làm thủ tục lên máy bay nội địa.

The US president is preparing executive actions to increase energy supply for AI expansion, Threads now offers independent word blocking, and China’s aviation regulator will prohibit passengers from carrying power banks on flights unless they bear the “3C” safety marking. MP3 Please SUBSCRIBE HERE for free or get DTNS Live ad-free. A special thanks toContinue reading "The US President Is Preparing Executive Actions To Increase Energy Supply For AI Expansion – DTH"

《360°生活家》－全面升級你的日常！ 想一次掌握生活資訊、科技新知、3C智慧與健康趨勢嗎？ 《360°生活家》每集帶你從不同角度探索生活的無限可能 無論是科技新品開箱、健康生活技巧，還是日常小撇步 都能讓你輕鬆成為生活達人，開啟更有品質的精彩人生！ 現在就跟著我們，360度全面升級你的生活吧！ 歡迎訂閱、收聽，每日更新精彩內容 陪你一起輕鬆享受智慧、健康、便利的美好生活！

《360°生活家》－全面升級你的日常！ 想一次掌握生活資訊、科技新知、3C智慧與健康趨勢嗎？ 《360°生活家》每集帶你從不同角度探索生活的無限可能 無論是科技新品開箱、健康生活技巧，還是日常小撇步 都能讓你輕鬆成為生活達人，開啟更有品質的精彩人生！ 現在就跟著我們，360度全面升級你的生活吧！ 歡迎訂閱、收聽，每日更新精彩內容 陪你一起輕鬆享受智慧、健康、便利的美好生活！

《360°生活家》－全面升級你的日常！ 想一次掌握生活資訊、科技新知、3C智慧與健康趨勢嗎？ 《360°生活家》每集帶你從不同角度探索生活的無限可能 無論是科技新品開箱、健康生活技巧，還是日常小撇步 都能讓你輕鬆成為生活達人，開啟更有品質的精彩人生！ 現在就跟著我們，360度全面升級你的生活吧！ 歡迎訂閱、收聽，每日更新精彩內容 陪你一起輕鬆享受智慧、健康、便利的美好生活！

《360°生活家》－全面升級你的日常！ 想一次掌握生活資訊、科技新知、3C智慧與健康趨勢嗎？ 《360°生活家》每集帶你從不同角度探索生活的無限可能 無論是科技新品開箱、健康生活技巧，還是日常小撇步 都能讓你輕鬆成為生活達人，開啟更有品質的精彩人生！ 現在就跟著我們，360度全面升級你的生活吧！ 歡迎訂閱、收聽，每日更新精彩內容 陪你一起輕鬆享受智慧、健康、便利的美好生活！

Dr. Allison Zibelli and Dr. Rebecca Shatsky discuss advances in breast cancer research that were presented at the 2025 ASCO Annual Meeting, including a potential new standard of care for HER2+ breast cancer, the future of ER+ breast cancer management, and innovations in triple negative breast cancer therapy. Transcript Dr. Allison Zibelli: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Allison Zibelli, your guest host of the podcast today. I'm an associate professor of medicine and a breast medical oncologist at the Sidney Kimmel Comprehensive Cancer Center at Jefferson Health. There was a substantial amount of exciting breast cancer data presented at the 2025 ASCO Annual Meeting, and I'm delighted to be joined by Dr. Rebecca Shatsky today to discuss some of these key advancements. Dr. Shatsky is an associate professor of medicine at UC San Diego and the head of breast medical oncology at the UC San Diego Health Moores Cancer Center, where she also serves as the director of the Breast Cancer Clinical Trials Program and the Inflammatory and Triple-Negative Breast Cancer Program.  Our full disclosures are available in the transcript of this episode. Dr. Shatsky, it's great to have you on the podcast today. Dr. Rebecca Shatsky: Thanks, Dr. Zibelli. It's wonderful to be here. Dr. Allison Zibelli: So, we're starting with DESTINY-Breast09, which was trastuzumab deruxtecan and pertuzumab versus our more standard regimen of taxane, trastuzumab pertuzumab for first-line treatment of metastatic HER2-positive breast cancer. Could you tell us a little bit about the study? Dr. Rebecca Shatsky: Yeah, absolutely. So, this was a long-awaited study. When T-DXd, or trastuzumab deruxtecan, really hit the market, a lot of these DESTINY-Breast trials were started around the same time. Now, this was a global, randomized, phase 3 study presented by Dr. Sara Tolaney from the Dana-Farber Cancer Institute of Harvard in Boston. It was assessing essentially T-DXd in the first-line setting for metastatic HER2-positive breast cancer in addition to pertuzumab. And that was randomized against our standard-of-care regimen, which was established over a decade ago by the CLEOPATRA trial, and we've all been using that internationally for at least the past 10 years. So, this was a large trial, and it was one-to-one-to-one of patients getting T-DXd plus pertuzumab, T-DXd alone, or THP, which mostly is used as docetaxel and trastuzumab and pertuzumab every three weeks for six cycles. And this was in over 1,000 patients; it was 1,159 patients with metastatic HER2-positive breast cancer. This was a very interesting trial. It was looking at the use of trastuzumab deruxtecan, but patients were started on this treatment for their first-line metastatic HER2-positive breast cancer with no end date to their T-DXd. So, it was, you know, you were started on T-DXd every 3 weeks until progression. Now, CLEOPATRA is a little bit different than that, though, as we know. So, CLEOPATRA has a taxane plus trastuzumab and pertuzumab. But generally, patients drop the taxane after about six to seven cycles because, as we know, you can't be really on a taxane indefinitely. You get pretty substantial neuropathy as well as cytopenias, other things that end up happening. And so, in general, that regimen has sort of a limited time course for its chemotherapy portion, and the patients maintained after the taxane is dropped on their trastuzumab and their pertuzumab, plus or minus endocrine therapy if the investigator so desires. And the primary endpoint of the trial was progression-free survival by blinded, independent central review (BICR) in the intent-to-treat population. And then it had its other endpoints as overall survival, investigator-assessed progression-free survival, objective response rates, and duration of response, and of course, safety. As far as the results of this trial, so, I think that most of us key opinion leaders in breast oncology were expecting that this was going to be a positive trial. And it surely was. I mean, this is a really, really active drug, especially in HER2-positive disease, of course. So, the DESTINY-Breast03 data really established that, that this is a very effective treatment in HER2-positive metastatic breast cancer. And this trial really, again, showed that. So, there were 383 patients that ended up on the trastuzumab plus deruxtecan plus pertuzumab arm, and 387 got THP, the CLEOPATRA regimen. What was really interesting also to note of this before I go on to the results was that 52% of patients on this trial had de novo metastatic disease. And that's pretty unusual for any kind of metastatic breast cancer trial. It kind of shows you, though, just how aggressive this disease is, that a lot of patients, they present with de novo metastatic disease. It's also reflecting the global nature of this trial where maybe the screening efforts are a little bit less than maybe in the United States, and more patients are presenting as later stage because to have a metastatic breast cancer trial in the United States with 52% de novo metastatic disease doesn't usually happen. But regardless, the disease characteristics were pretty well matched between the two groups. 54% of the patients were triple positive, or you could say hormone-positive because whether they were PR positive or ER positive and PR negative doesn't really matter in this disease. And so, the interim data cutoff was February of this year, of 2025. So, the follow-up so far has been about 29 months, so the data is still really immature, only 38% mature for progression-free survival interim analysis. But what we saw is that T-DXd plus pertuzumab, it really improved progression-free survival. It had a hazard ratio that was pretty phenomenal at 0.56 with a confidence interval that was pretty narrow of 0.44 to 0.71. So, very highly statistically significant data here. The progression-free survival was consistent across all subgroups. Overall survival, very much immature at this time, but of course, the trend is towards an overall survival benefit for the T-DXd group. The median durable response with T-DXd plus pertuzumab exceeded 3 years. Now, importantly, though, I want to stress this, is grade 3 or above treatment-emergent adverse events occurred in both subgroups pretty equally. But there were 2 deaths in the T-DXd group due to interstitial lung disease. And there was a 12.1% adjudicated drug-induced interstitial lung disease/pneumonitis event rate in the T-DXd group and only 1%, and it was grade 1-2, in the THP group. So, that's really the caveat of this therapy, is we know that a percentage of patients are going to get interstitial lung disease, and that some may have very serious adverse events from it. So, that's always something I keep in the back of my mind when I treat patients with T-DXd. And so, overall, the conclusions of the trial were pretty much a slam dunk. T-DXd plus pertuzumab, it had a highly statistically significant and clinically meaningful improvement in progression-free survival versus the CLEOPATRA regimen. And that was across all subgroups for first-line metastatic HER2-positive breast cancer here. And so, yeah, the data was pretty impressive. Just to go into the overall response rate, because that's always super important as well, you had 85.1% of patients having a confirmed overall RECIST response rate in the T-DXd plus pertuzumab group and a 78.6 in the CLEOPATRA group. The complete CR rate, complete response was 15.1% in the T-DXd group and 8.5 in the CLEOPATRA regimen. And it was really an effective regimen in this group, of course. Dr. Allison Zibelli: So, the investigators say at the end of their abstract that this is the new standard of care. Would you agree with that statement? Dr. Rebecca Shatsky: Yeah, that was a bold statement to make because I would say in the United States, not necessarily at the moment because the quality of life here, you have to think really hard about. Because one thing that's really important about the DESTINY-Breast09 data is that this was very much an international trial, and in many of the countries where patients enrolled on this, they were not able to access T-DXd off trial. And so, for them, this means T-DXd now or potentially never. And so, that is a really big difference whereas internationally, that may mean standard of care. However, in the US, patients have no issues accessing T-DXd in the second- or third-line settings. And right now, it's the standard of care in the second line in the United States, with all patients basically getting this second-line therapy except for some unique patients where they may be doing a PATINA trial regimen, which we saw at San Antonio Breast Cancer in 2024 of the triple-positive patients getting hormonal therapy plus palbociclib, which had a really great durable response. That was super impressive as well. Or there is the patient that the investigator can pick KADCYLA because the patient really wants to preserve their hair or maybe it's more indolent disease. But the quality of life on T-DXd indefinitely in the first-line setting is a big deal because, again, that CLEOPATRA regimen allows patients to drop their chemotherapy component about five to six months in. And with this, you're on a drug that feels very chemo-heavy indefinitely. And so, I think there's a lot more to investigate as far as what we're going to do with this data in the United States because it's a lot to commit a patient in the first-line metastatic setting. These de novo metastatic patients, some of them may be cured, honestly, on the HER2-targeting regimen. That's something we see these days. Dr. Allison Zibelli: So, very interesting trial. I'm sure we'll be talking about this for a long time.  So, let's move on to SERENA-6, which was, I thought, a very interesting trial. This trial took patients with ER positive, advanced breast cancer after six months on an AI (aromatase inhibitor) and a CDK4/6 inhibitor. They did ctDNA every two to three months, and when they saw an ESR1 mutation emerge, they changed half of the patients to camizestrant plus CDK4/6 and kept the other half on the AI plus CDK4/6. Can you talk about that trial a little bit, please? Dr. Rebecca Shatsky: Yeah, so this was a big trial at ASCO25. This was presented as a Plenary Session. So, this was camizestrant plus a CDK4/6 inhibitor, and it could have been any of the three, so palbo, ribo, or abemaciclib in the first-line metastatic hormone-positive population, and patients were on an AI with that. They were, interestingly, tested by ctDNA at baseline to see if they had an ESR1 mutation. So, that was an interesting feature of this trial. But patients had to have already been on their CDK4/6 inhibitor plus AI for at least 6 months to enroll. And then, as you mentioned, they got ctDNA testing every 2 to 3 months. This was also a phase 3, double-blind, international trial. And I do want to highlight again, international here, because that's important when we're considering some of this data in the U.S. because it influences some of the results. So, this was presented by Dr. Nick Turner of the Royal Marsden in the UK. So, just a little bit of background for our listeners on ESR1 mutations and why they're important. This is the most common, basically, acquired resistance mutation to patients being treated with aromatase inhibitors. We know that treatment with aromatase inhibitors can induce this. It makes a conformational change in the estrogen receptor that makes the estrogen receptor constitutively active, which allows the cell to signal despite the influence of the aromatase inhibitor to decrease the estrogen production so that the ligand binding doesn't matter as much as far as the cell signaling and transcription is concerned. And camizestrant, you know, as an oral SERD, just to explain that a little bit too; these are estrogen receptor degraders. The first-in-class of a selective estrogen receptor degrader to make it to market was fulvestrant. And that's really been our standard-of-care estrogen degrader for the past 25 years, almost 25 years. And so, a lot of us are just looking for some of these oral SERDs to replace that. But regardless, they do tend to work in the ESR1-mutated population. And we know that patients on aromatase inhibitors, the estimates of patients developing an ESR1 mutation, depending on which study you look at, somewhere between 30% to 50% overall, patients will develop this mutation with hormone-positive metastatic breast cancer. There is a small percentage of patients that have these at baseline without even treatment of an aromatase inhibitor. The estimates of that are somewhere between 0.5 and up to 5%, depending on the trial you look at and the population. But regardless, there is a chance someone on their CDK4/6 inhibitor plus AI at 6 months' time course could have had an ESR1 mutation at that time. But anyway, so they got this ctDNA every 2 to 3 months, and once they were found to develop an ESR1 mutation, the patients were then switched to the oral SERD. AstraZeneca's version of the oral SERD is camizestrant, 75 mg daily. And then their type of CDK4/6 inhibitor was maintained, so they didn't switch the brand of their CDK4/6 inhibitor, importantly. And that was looked at then for progression-free survival, but these were patients with measurable disease by RECIST version 1.1. And the data cut off here was November of 2024. This was a big trial, you know, and I think that that's influential here because this was 3,256 patients, and that's a lot of patients. So, they were all eligible. And then 315 patients ended up being randomized to switch to camizestrant upon presence of that ESR1 mutation. So, that was 157 patients. And then the other half, so they were randomized 1:1, they continued on their AI without switching to an oral SERD. That was 158 patients. They were matched pretty well. And so, their baseline characteristics, you know, the two subgroups was good. But this was highly statistically significant data. I'm not going to diminish that in any way. Your hazard ratio was 0.44. Highly statistically significant confidence intervals. And you had a median progression-free survival in those that switched to camizestrant of 16 months, and then the non-switchers was 9.2 months. So, the progression-free survival benefit there was also consistent across the subgroups. And so, you had at 12 months, the PFS rate was 60.7% for the non-treatment group and 33.4% in the treatment group. What's interesting, though, is we don't have overall survival data. This is really immature, only 12% mature as far as overall survival. And again, because this was an international trial and patients in other countries right now do not have the access to oral SERDs that the United States does, the crossover rate, they were not allowed to crossover, and so, a very few patients, when we look at progression-free survival 2 and ultimately overall survival, were able to access an oral SERD in the off-trial here and in the non-treatment group. And so, that's really important as far as we look at these results. Adverse events were pretty minimal. These are very safe drugs, camizestrant and all the other oral SERDs. They have some mild toxicities. Camizestrant is known for something weird, which is called photopsia, which is some flashing lights in the periphery of the eye, but it doesn't seem to have any serious clinical significance that we know of. It has a little bit of bradycardia, but it's otherwise really well tolerated. You know, I hate to say that because that's very subjective, right? I'm not the one taking the drug. But it doesn't have any serious adverse events that would cause discontinuation. And that's really what we saw in the trial. The discontinuation rates were really low. But overall, I mean, this was a positive trial. SERENA-6 showed that switching to camizestrant at the first sign of an ESR1 mutation on CDK4/6 inhibitor plus AI improved progression-free survival. That's all we can really say from it right now. Dr. Allison Zibelli: So, let's move on to ASCENT-04, which was a bit more straightforward. Sacituzumab govitecan plus pembrolizumab versus chemotherapy plus pembrolizumab in PD-L1-positive, triple-negative breast cancer. Could you talk about that study? Dr. Rebecca Shatsky: Yeah, so this was also presented by the lovely Sara Tolaney from Dana-Farber. And this study made me really excited. And maybe that's because I'm a triple-negative breast cancer person. I mean, not to say that I don't treat hundreds of patients with hormone- positive, but our unmet needs in triple negative are huge because this is a disease where you have got to throw your best available therapy at it as soon as you can to improve survival because survival is so poor in this disease. The average survival with metastatic triple-negative breast cancer in the United States is still 13-18 months, and that's terrible. And so, for full disclosure, I did have this trial open at my site. I was one of the site PIs. I'm not the global PI of the study, obviously. So, what this study was was for patients who had had at least a progression-free survival of 6 months after their curative intent therapy or de novo metastatic disease. They were PD-L1 positive as assessed by the Dako 22C3 assay of greater than or equal to a CPS score of 10. So, that's what the KEYNOTE-355 trial was based on as well. So, standard definition of PD-L1 positive in breast cancer here. And basically, these patients were randomized 1:1 to either their sacituzumab govitecan plus pembrolizumab, day 1 they got both therapies, and then day 8 just the saci, as is standard for sacituzumab. And then the other group got the KEYNOTE-355 regimen. So, that is pembrolizumab with – your options are carbogem there, paclitaxel or nab-paclitaxel. And it's up to investigator's decision which upon those they decided. They followed these patients for disease progression or unacceptable toxicity. It was really an impressive trial in my opinion because we know already that this didn't just improve progression-free survival, because survival is so poor in this disease, of course, we know that it improved overall survival. It's trending towards that very much, and I think that's going to be shown immediately. And then the objective response rates were better, which is key in this disease because in the first-line setting, you've got a lot of people who, especially your relapsed TNBC that don't respond to anything. And you lose a ton of patients even in the first-line setting in this disease. And so, this was 222 patients to chemotherapy and pembro and 221 to sacituzumab plus pembro. Median follow-up has only been 14 months, so it's still super early here. Hazard ratio so far of progression-free survival is 0.65, highly statistically significant, narrow confidence intervals. And so, the median duration of response here for the saci group was 16.5 months versus 9.2 months. So, you're getting a 7-month progression-free survival benefit here, which in triple negative is pretty fantastic. I mean, this reminds me of when we saw the ASCENT data originally come out for sacituzumab, and we were all just so happy that we had this tool now that doubled progression-free and overall survival and made such a difference in this really horrible disease where patients do poorly. So, OS is technically immature here, but it's really trending very heavily towards improvement in overall survival. Importantly, the treatment-related adverse events in this, I mean, we know sacituzumab causes neutropenia, people who are experienced with this drug know how to manage it at this point. There wasn't any really unexpected treatment-related adverse events. You get some people with sacituzumab who have diarrhea. It's usually pretty manageable with some Imodium. So, it was cytopenias predominantly in this disease in this population that were highlighted as far as adverse events. But I'm going to be honest, like I was surprised that this wasn't the plenary over the SERENA-6 data because this, in my mind, there we have a practice-changing trial. I will immediately be trying to use this in my PD-L1 population because, to be honest, as a triple-negative breast cancer clinical specialist, when I get a patient with metastatic triple-negative breast cancer who's PD-L1 positive, I think, "Oh, thank God," because we know that part of the disease just does better in general. But now I have something that really could give them a durable response for much longer than I ever thought possible when I started really heavily treating this disease. And so, this was immediately practice-changing for me. Dr. Allison Zibelli: I think that it's pretty clear that this is at least an option, if not the option, for this group of patients. Dr. Rebecca Shatsky: Yeah, the duration of responses here was – it's just really important because, I mean, I do think this will make people live longer. Dr. Allison Zibelli: So, moving on to the final study that we're going to discuss today, neoCARHP (LBA500), which was neoadjuvant taxane plus trastuzumab, pertuzumab, plus or minus carbo(platin) in HER2-positive early breast cancer. I think this is a study a lot of us have been waiting for. What was the design and the results of this trial? Dr. Rebecca Shatsky: I was really excited about this as well because I'm one of those people that was waiting for this. This is a Chinese trial, so that is something to take note of. It wasn't an international trial, but it was a de-escalation trial which had become really popular in HER2-positive therapy because we know that we're overtreating HER2-positive breast cancer in a lot of patients. A lot of patients we're throwing the kitchen sink at it when maybe that is not necessary, and we can really de-escalate and try to personalize therapy a little bit better because these patients tend to do well. So, the standard of care, of course, in HER2-positive curative intent breast cancer with tumors that are greater than 2 cm is to give them the TCHP regimen, which is docetaxel, carboplatin, trastuzumab, and pertuzumab. And that was sort of established by several trials in the NeoSphere trial, and now it's been repeated in a lot of different studies as well. And so, that's really the standard of care that most people in the United States use for HER2-positive curative intent breast cancer. This was a trial to de-escalate the carboplatin, which I was super excited about because many of us who treat this disease a lot think carbo is the least important part of the therapy you're giving there. We don't really know that it's necessary. We've just been doing it for a long time, and we know that it adds a significant amount of toxicity. It causes thrombocytopenia, it causes severe nausea, really bad cytopenias that can be difficult in the last few cycles of this to manage. So, this trial was created. It randomized patients one to one with stage 2 and 3 HER2-positive breast cancer to either get THP, a taxane, pertuzumab, trastuzumab, similar to the what we do in first-line metastatic HER2-positive versus the whole TCHP with a carboplatin AUC of 6, which is what's pretty standard. And it was a non-inferiority trial, so important there. It wasn't to establish superiority of this regimen, which none of us, I think, were looking for it to. And it was a modified intent-to-treat population. And so, all patients got at least one cycle of this to be assessed as a standard for an intent-to-treat trial. And so, they assumed a pCR rate of about 62.8% for both groups. And, of course, it included both HER2-positive triple positives and ER negatives, which are, you know, a bit different diseases, to be honest, but we all kind of categorize them and treat them the same. And so, this trial was powered appropriately to detect a non-inferiority difference. And so, we had about 380 patients treated on both arms, and there was an absolute difference of only 1.8% of those treated with carbo versus those without. Which was fantastic because you really realized that de-escalation here may be something we can really do. And so, the patients who got, of course, the taxane regimen had fewer adverse events. They had way fewer grade 3 and 4 adverse events than the THP group. No treatment-associated deaths occur, which is pretty standard for- this is a pretty safe regimen, but it causes a lot of hospitalizations due to diarrhea, due to cytopenias, and neutropenic fever, of course. And so, I thought that this was something that I could potentially enact, you know, and be practice-changing. It's hard to say that when it's a trial that was only done in China, so it's not necessarily the United States population always. But I think for patients moving forward, especially those with, say, a 2.5 cm tumor, you know, node negative, those, I'd feel pretty comfortable not giving them the carboplatin here. Notes that I want to make about this population is that the majority were stage 2 and not stage 3. They weren't necessarily your inflammatory HER2-positive breast cancer patients. And that the taxane that was utilized in the trial is a little different than what we use in the United States. The patients were allowed to get nab-paclitaxel, which we don't have FDA approval for in the first-line curative intent setting for HER2-positive breast cancer in the United States. So, a lot of them got abraxane, and then they also got paclitaxel. We tend to use docetaxel every 3 weeks in the United States. So, just to point out that difference. We don't really know if that's important or not, but it's just a little bit different to the population we standardly treat. Dr. Allison Zibelli: So, are there patients that you would still give TCHP to? Dr. Rebecca Shatsky: Yeah, great question. I've been asked that a lot in the past like week since ASCO. I'd say in my inflammatory breast cancer patients, that's a group I do tend to sometimes throw the kitchen sink at. Now, I don't actually use AC in those because I know that that was the concern, but I think the TRAIN-2 trial really showed us you don't need to use Adriamycin in HER2-positive disease unless it's like refractory. So, I don't know that I would throw this on my stage 3C or inflammatory breast cancer patients yet because the majority of this were not stage 3. So, in your really highly lymph node positive patients, I'm a little bit hesitant to de-escalate them from the start. This is more of a like, if there's serious toxicity concerns, dropping carbo is absolutely fine here. Dr. Allison Zibelli: All right, great.  Thank you, Dr. Shatsky, for sharing your valuable insights with us on the ASCO Daily News Podcast today. Dr. Rebecca Shatsky: Thanks so much, Dr. Zibelli and ASCO Daily News. I really want to thank you for inviting me to talk about this today. It was really fun, and I hope you find my opinions on some of this valuable. And so, I just want to thank everybody and my listeners as well. Dr. Allison Zibelli: And thank you to our listeners for joining us today. You'll find the links to all the abstracts discussed today in the transcript of this episode. Finally, if you like this podcast and you learn things from it, please take a moment to rate, review, and describe because it helps other people find us wherever you get your podcasts. Thank you again. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers Dr. Allison Zibelli Dr. Rebecca Shatsky @Dr_RShatsky Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn   Disclosures: Dr. Allison Zibelli: No relationships to disclose Dr. Rebecca Shatsky: Consulting or Advisory Role: Stemline, Astra Zeneca, Endeavor BioMedicines, Lilly, Novartis, TEMPUS, Guardant Health, Daiichi Sankyo/Astra Zeneca, Pfizer Research Funding (Inst.): OBI Pharma, Astra Zeneca, Greenwich LifeSciences, Briacell, Gilead, OnKure, QuantumLeap Health, Stemline Therapeutics, Regor Therapeutics, Greenwich LifeSciences, Alterome Therapeutics  

《360°生活家》－全面升級你的日常！ 想一次掌握生活資訊、科技新知、3C智慧與健康趨勢嗎？ 《360°生活家》每集帶你從不同角度探索生活的無限可能 無論是科技新品開箱、健康生活技巧，還是日常小撇步 都能讓你輕鬆成為生活達人，開啟更有品質的精彩人生！ 現在就跟著我們，360度全面升級你的生活吧！ 歡迎訂閱、收聽，每日更新精彩內容 陪你一起輕鬆享受智慧、健康、便利的美好生活！

現代人天天盯著螢幕，你的眼睛還好嗎？ 本集帶你了解日常生活中如何透過營養補充，守護眼睛健康不被藍光傷害！ 從黃斑部的守門員——葉黃素與玉米黃素，到舒緩眼壓的蝦紅素，再到滋潤雙眼的魚油Omega-3，一次搞懂三大關鍵營養素，適合長時間用眼的你！

Welcome to episode 176 of Growers Daily! We cover: garlic curing and storage, the overlooked relationship between manufacturing and farm land, and flower power. But the easy way.  We are a Non-Profit! 

In this episode of The Internal Comms Podcast, host Katie Macaulay sits down with alignment strategist and leadership coach Zora Artis to explore a crucial question: how can internal comms teams unite people around what matters most? It's no easy task, but Zora brings three decades of in-the-trenches experience. As CEO of Artis Advisory, co-founder of the Alignment People and a partner at Mirror Mirror Alignment, her work focuses on getting leaders and teams unstuck and helping organisations untangle competing priorities, find common ground and move forward with confidence. As Zora's research shows, only 13% of organisations achieve real alignment and she explains why diagnosing the real problem matters more than simply turning up the volume on messaging. Misalignment often hides in plain sight, masked by polite nods, surface-level agreement and subtle misunderstandings, she says. Meaningful, facilitated dialogue – not broadcast communication – is often the missing piece. She also introduces her ‘3C+' model and cohesion cycle: practical frameworks to help teams stay agile, find purpose and work as one. Along the way, Zora shares lessons from elite sport, psychology and her own leadership journey, where curiosity, courage and a little discomfort all play a role. As always, we'd love to hear your thoughts. Use the hashtag #TheICPodcast to join the conversation, and thank you for listening.

－挺你所想！與你一起生活的銀行－ 中國信託銀行APP超越大升級， 眾多好用功能，力挺你的金融需求！ 趕緊註冊行動銀行，就送OPENPOINT100點。 立即點擊連結看活動詳情～ https://sofm.pse.is/7nyp36 -- 住近美術館，把握最後機會 《惟美術》3房熱銷倒數 輕奢品味，全新完工，即刻入住 近鄰輕軌C22站，設籍明星學區 預約來電 07-553-3838 https://sofm.pse.is/7nyp2z －－－－以上訊息由 SoundOn 動態廣告贊助商提供－－－－ 飛碟聯播網《飛碟早餐 唐湘龍時間》2025.06.03 週二醫療保健單元 專訪：台大醫院眼科部主治醫師｜楊中美 主題：《好眼力：台大眼科名醫楊中美教你正確認識及防護眼睛疾病》天下文化 好書收藏 https://reurl.cc/pajqr4 對抗3C時代惡視力！你一定要知道的眼疾與保健觀念 擁有正確的護眼知識，能有效從源頭杜絕眼睛疾病的發生 台大眼科楊中美醫師行醫與教學40餘年，看診名額一位難求，寶貴知識經驗首度出版成冊。本書涵蓋多領域眼科知識，幫助大眾破解常見護眼保健迷思，有效從源頭杜絕眼睛疾病的發生。 作者簡介 楊中美 台大醫學系畢業，台大醫學院名譽教授、中華民國視網膜醫學會共同創始人。現為台大醫院眼科部主治醫師，曾任台大醫院眼科部主任、中華民國視網膜醫學會理事長。專長於視網膜及玻璃體疾患之診治。 身為國際視網膜領域著名學者，多次受邀於亞太眼科醫學會、亞太玻璃體視網膜學會、各國眼科醫學會、兩岸眼科醫學會等學會演講。2016年當選亞太眼科教授學院院士，並獲頒亞太眼科醫學會成就獎。 常以「術精德厚」自勉，持續專注於糖尿病視網膜病變與黃斑部疾患的診治、教學及前沿研究，推廣大眾的眼部保健。 #眼睛 #眼科#視網膜#台大醫院#楊中美#黃斑部#白內障#飛蚊症#醫療#保健#視力#老花眼 ▶ 《飛碟早餐》FB粉絲團  / ufobreakfast  ▶ 飛碟聯播網FB粉絲團  / ufonetwork921  ▶ 網路線上收聽 http://www.uforadio.com.tw ▶ 飛碟APP，讓你收聽零距離 IOS：https://reurl.cc/3jYQMV Android：https://reurl.cc/5GpNbR ▶ 飛碟Podcast Apple Podcasts : https://apple.co/3jFpP6x Spotify : https://spoti.fi/2CPzneD KKBOX：https://reurl.cc/MZR0K4 -- Hosting provided by SoundOn

欢迎收听雪球出品的财经有深度，雪球，国内领先的集投资交流交易一体的综合财富管理平台，聪明的投资者都在这里。今天分享的内容叫美团：短期超预期、中期看竞争、长期看监管，来自星海游心。短期超预期：财报表现强劲，核心业务韧性凸显2025年一季度，美团交出了一份超出市场预期的成绩单。财报显示，公司总营收同比增长18.1%至866亿元，净利润同比大增87.3%至101亿元，调整后净利润达109亿元，同比增长46.2%。这一表现得益于核心本地商业与新业务的双轮驱动：核心本地商业收入643亿元，经营溢利135亿元；新业务收入222亿元，经营亏损收窄17.5%至2.3亿元。1.外卖与闪购业务齐头并进外卖业务保持健康增长，用户粘性和购买频次进一步提升。美团创新推出的“品牌卫星店”模式成效显著，截至一季度已助力480多个品牌开出3000家卫星店，有效丰富了外卖供给。闪购业务更是成为亮点，非餐饮品类即时零售日单量突破1800万单，饮料零食、3C产品、家用电器等品类增长显著，累计交易用户数超5亿，其中90后年轻消费者占比达三分之二。闪购业务的快速扩张不仅带动了骑手收入增长，还通过高毛利品类优化了收入结构。2.到店酒旅业务稳健增长到店酒旅订单量同比增长超50%，年度交易用户及活跃商家数均创历史新高。升级后的“神会员”计划成为新增长动力，通过整合全生活场景权益，有效提升了用户复购率。在高星酒店领域，美团与全球品牌合作推出“酒店+X”打包产品；在下沉市场，数字化渗透加速，为低线城市用户提供了更多高性价比选择。3.新业务减亏与国际化突破新业务亏损同比收窄55%至21.8亿元，经营亏损率从26%降至9.5%。海外市场方面，Keeta在沙特表现亮眼，凭借高效配送和本地化运营赢得用户认可，并计划于近期进入巴西市场。国内新业务如B2B餐饮供应链、共享单车等持续巩固市场地位，为长期增长奠定基础。中期看竞争：京东、抖音正面交锋，阿里生态协同施压尽管短期业绩亮眼，美团中期面临的竞争压力呈现多元化特征。京东以外卖为切入点直击高频场景，抖音通过内容流量重构到店生态，阿里则依托电商与支付生态渗透即时零售，三方形成差异化博弈格局。1. 京东外卖闪电破局：高频带低频的战略博弈京东凭借“骑手五险一金+商家免佣金+百亿补贴”策略，外卖日订单量在上线75天后突破2000万单，单均补贴力度达10元。其核心逻辑是通过外卖高频场景为零售业务引流，形成“外卖亏损、零售盈利”的交叉补贴模式。尽管美团日均单量仍达6000万单，规模效应下配送成本优势显著，但京东的激进策略可能导致美团Q2核心本地商业收入增速放缓至10%以下，经营利润率环比下滑。京东的竞争本质是“零售巨头对本地生活的降维打击”，其供应链能力与美团闪购形成直接竞争。2.抖音内容渗透：重构本地生活流量入口抖音已成为美团到店业务的最大威胁。2024年其本地生活GMV达5600亿元，同比增长81%，2025年目标直指8000亿元。抖音通过短视频、直播、POI标签等内容形态，将“种草-交易-履约”链路闭环，覆盖商家超610万家，达人探店带动商家收入增长53%。在年轻用户中，抖音“先看内容再消费”的习惯已形成替代效应，其在综合类目的覆盖率已超美团，到店餐饮订单量占美团的比例从2023年的15%提升至2025年Q1的32%。尽管美团在核销后服务仍占优，但抖音通过“门店直播秒杀”等模式，正在抢夺商家的流量预算和用户心智。3.阿里生态协同：流量与供应链的双重施压阿里虽未直接以“外卖”作为主攻方向，但依托电商生态与支付入口，形成多维度渗透：即时零售：淘宝闪购日均订单量突破800万单，整合饿了么配送网络与淘宝天猫品牌资源，推出“1小时达”数码家电、服饰美妆等品类，依托8.74亿淘宝月活用户，以“低价秒杀+社交裂变”分流美团闪购用户；外卖业务：饿了么通过“超时免罚”“灵活考核”优化骑手体验，联合淘宝推出“1.4元茶饮”“19.9元星巴克”等低价套餐，2025年Q1外卖日单量回升至3500万单；到店业务：支付宝“生活号”与口碑联动，以“支付即会员”模式切入中小商家，重点拓展社区餐饮、便利店等场景，虽GMV规模仅为抖音的1/3，但依托阿里88VIP会员体系形成差异化复购。阿里的竞争逻辑是“生态协同而非单一品类突破”，其供应链优势与美团闪购形成直接对标，支付入口则威胁美团收银系统的市场份额。长期看监管：合规成本上升与行业生态重构随着中国对平台经济监管趋严，美团需在合规与发展间寻求平衡，长期增长将更多依赖政策适配能力。1.骑手权益保障持续加码监管部门对灵活就业人员社保问题高度关注。美团自2022年起试点职业伤害险，已为7个省市近700万骑手缴纳15亿元保费，并计划2025年将覆盖范围扩展至全国。2025年4月启动的养老保险试点方案已在南通、泉州落地，预计未来将逐步推广至百万骑手。此外，美团取消配送超时罚款、试点“等灯等灯奖”等举措，旨在改善骑手工作条件，降低舆论风险。合规成本方面，预计2025-2027年，骑手社保支出将使美团年均净利润减少3%-5%。2.平台收费行为规范化市场监管总局2025年5月发布的《网络交易平台收费行为合规指南（征求意见稿）》明确禁止重复收费、只收费不服务等8类不合理行为，并要求平台公示营销推广费规则。这可能压缩美团佣金和广告收入空间，尤其是到店酒旅业务的高佣金模式面临调整压力。美团已通过“十亿助力金计划”补贴商家，并承诺未来三年投入1000亿元支持行业高质量发展，以缓解监管带来的成本压力。3.反垄断与数据安全风险尽管美团在本地生活领域尚未被认定为垄断，但监管层对“二选一”、数据滥用等问题的关注持续存在。例如，抖音通过流量优势要求商家“优先在抖音开展直播团购”，可能引发对平台生态公平性的审查；美团则需在用户数据收集、骑手轨迹监控等方面加强合规，避免因数据安全问题引发处罚。海外扩张方面，Keeta在沙特等市场需遵守当地劳工法和数据主权要求，合规成本较国内更高。短期韧性与长期挑战并存1.短期超预期验证商业模式优势美团凭借规模效应、精细化运营和全场景协同，在2025年一季度实现了营收与利润的双增长。闪购业务的爆发、到店酒旅的结构性优化以及新业务减亏，均体现了其商业模式的韧性。尽管二季度面临京东、抖音、阿里的多维竞争，但市场已对悲观预期有所定价，股价回调为长期投资者提供了入场机会。2.中期竞争将重塑行业格局京东、抖音、阿里的入局使行业从“双寡头”转向“多元博弈”：京东以资本补贴冲击外卖基本盘，抖音以内容流量重构到店逻辑，阿里以生态协同渗透即时零售。美团的应对策略需更具针对性：对京东需强化配送成本优势与商家补贴效率，对抖音需加快内容化转型，对阿里需巩固中小商家数字化壁垒。竞争可能导致行业利润率短期承压，但长期来看，具备技术迭代能力和生态粘性的平台将主导市场。3.长期监管驱动行业良性发展监管政策虽增加了合规成本，但也推动行业从“规模优先”转向“质量优先”。美团通过骑手社保、商家数字化扶持等举措，正在构建更可持续的生态系统。此外，监管对数据安全和公平竞争的要求，将倒逼美团提升技术透明度和商业模式创新，为其海外扩张积累经验。例如，Keeta在沙特的本地化运营已采用“政府监管+平台自治”模式，未来可复制至其他市场。总体而言，美团在短期展现出强劲的增长动能，中期需在多元竞争中动态调整策略，长期则需在监管框架下探索“效率与公平平衡”的新范式。投资者应关注其核心业务的盈利稳定性、技术投入的转化效率以及全球化布局的进展，以把握行业变革中的结构性机会。

高雄美術特區3-4房全新落成，《惟美術》輕軌C22站散步即到家，近鄰青海商圈，卡位明星學區，徜徉萬坪綠海。 住近美術館，擁抱優雅日常，盡現驕傲風範！美術東四路29號 07-553-3838 https://sofm.pse.is/7melqb --

今回は「極端な暑さがもたらす、暮らしの変化」（世界経済フォーラム３月３１日掲載）の記事を話題に、暑さによる健康被害や、私達の思考力への影響などについておしゃべりします。https://jp.weforum.org/stories/2025/03/extreme-heat-is-changing-the-way-we-live-this-is-how/#%3Cb%3E%E6%97%A5%E3%80%85%E3%81%AE%E7%94%9F%E6%B4%BB%E7%BF%92%E6%85%A3%E3%81%8C%E5%A4%89%E5%8C%96%3C/b%3E

最堅持考究兩岸史實的Podcast節目！聽歷史系文人老譚與大德，從近代看現代、從國共談兩岸。 ⭐ 隨喜贊助製作更優質內容 https://bit.ly/3jL5K0c ⭐ 與老譚聯絡 podcast@ettoday.net ⭐ Apple用戶請給我們★★★★★ ⭐ 訂閱YT頻道: https://bit.ly/3bty9Sd －－－－以下訊息由 SoundOn 動態廣告贊助商提供－－－－

In this episode Zackavelli talks about the 3C's Game Design Framework Skip to Body of Episode: 6:15 Become a Patron: www.patreon.com/GDFG Join the discord and talk with the community about making video games! Link: discord.gg/2C8eTsU Follow Zackavelli on Twitter @_Zackavelli_ Twitch: www.twitch.tv/zackavelli_ Intro music by: Avaren Outro remix by: Mugamoomoo

【減壓自癒力｜重拾內在平衡的七場身體練習】

你有寫日記的習慣嗎？曾經最久堅持過幾天呢？ 隨著AI 發展越來越全面，現在連日記都可以連上 AI！今天要來和大家聊聊的這個軟體超級酷，就是利用AI 讓你邊寫日記，還可以和歷史名人對話，讓他們幫你解惑！ 馬上就一起來歡迎今天的大來賓 Life Note 創辦人 Daniel 陳韋亘！ - - - - - -- - - - - - 【寶博朋友說千萬粉絲專屬社群頻道 Discord 開張啦

這裡是樂天桃猿球迷向的非官方Podcast，請善用時間標記選擇想聽的話題。 ++++++ ** 『永豐銀行合作推廣』** 永豐SPORT卡是一張用汗水賺回饋的信用卡，只要每月加入永豐銀行的“汗水不白流”APP，參加【支持運動Podcast】揪團活動，達成app裡設計的運動目標，同時當月刷永豐SPORT卡，永豐銀行就會幫你抖內大叔野球543，抖內金額是每個卡戶刷卡消費的1%，或是一個人最多上限50元/月，再加上卡片本身是有最高6%回饋，就算運動沒達標，仍然有不錯的回饋讓大家來參考。支持永豐sport卡，支持大叔野球543，我們每年都會提撥固定比例跟你贊助基層棒球。 最後還是要謹慎理財，信用至上 申辦SPORT卡：https://mma.tw/O03BB ** ++++++** ** 聽友留言 (01:10)** ** 傷兵名單 (01:50)** ++++++ ** 上週比賽回顧 (03:58)** ** 戰績、團隊數據及個人成績 (09:33)** ** 本週賽程 (12:17)** ** ++++++** ** 非關桃猿** ** 組織文化 (12:46)** ** 勿隨便散播不該散播的內容 (16:03)** ** 有關桃猿** ** 辛苦的延賽等待(17:35)** ** ++++++** ** 非關棒球：新幹線驚爆倒數 (21:17)** --- 本獨立單元是針對樂天桃猿的各種動態以球迷視角製作的節目；主要的內容除了賽事回顧，還有聊聊其他球場內外的相關話題。因為球場不靠海，怕食材不新鮮所以不餵你吃整鍋牡蠣，因為考量牙齒保健，所以酸度大概至少讓你喝到醋。 這是一個主要聊台灣棒球的Podcast節目，我們沒有精闢的解說，也沒有專業的數據，就是幾個愛棒球的大叔和聽眾們一同喇賽、一同嘴砲~~ 大家可以在相關的 Podcast APP 收聽我們的節目，希望大家可以介紹給喜愛棒球的朋友們。 如果喜歡我們的節目，也希望大家可以在 Apple Podcast 專區給我們五顆星。 有興趣合作的廠商歡迎私訊或email聊聊 email：baseballuncle543@outlook.com IG：baseballuncle543 FB：大叔野球543 －－－－以下訊息由 SoundOn 動態廣告贊助商提供－－－－ 宏國德霖科技大學，有豐富獎學金就學補助、多元實習機會，讓你畢業即就業，實踐創業夢想人生！ 三大學院：餐旅學院、不動產學院及工程學院，緊密合作旗下凱撒飯店連鎖及宏國建設集團，宏國德霖科技大學是你最佳選擇！ https://sofm.pse.is/7kmz4c -- ✨宏匯廣場 歡慶璀璨女王節✨

這裡是台鋼雄鷹球迷視角觀察日記！ 請大家多多支持高雄在地新球隊。 使用的開頭音樂感謝台鋼雄鷹球團授權 中間的配樂都是由本人創作 大叔野球543 的贊助方案在嘖嘖上架囉， **請聽眾們多多支持： ** https://www.zeczec.com/projects/BaseballUncle543 『永豐銀行合作推廣』 永豐SPORT卡是一張用汗水賺回饋的信用卡， 只要每月加入永豐銀行的“汗水不白流”APP，參加【支持運動Podcast】揪團活動，達成app裡設計的運動目標， 同時當月刷永豐SPORT卡，永豐銀行就會幫你抖內大叔野球543，抖內金額是每個卡戶刷卡消費的1%，或是一個人最多上限50元/月，再加上卡片本身是有最高6%回饋，就算運動沒達標，仍然有不錯的回饋讓大家來參考。支持永豐sport卡，支持大叔野球543，我們每年都會提撥固定比例跟你贊助基層棒球。 最後還是要謹慎理財，信用至上 申辦SPORT卡：https://mma.tw/O03BB 上一集的羊肉燴飯： 廟口大港羊肉 https://g.co/kgs/vx1rRNb 掰咖老師的運動喇低賽： https://www.sportsv.net/authors/byka0217 0. 閒聊：啾謙帶頭關注聲援愷愷案❤️ 1. 打狗看球怎麼吃：雪花冰與鍋燒麵麵的結合？ 2. 鷹News：練習生，失誤、盜壘、國家隊。 3. 鷹 My Heart：同學會，源起。 4. 本週戰報：大哥開轟一直爽，瑞恩來亂金無奈。 5.雄雄想到：不敗金身，後勁！ 6.初鷹未來：保勝大弟，飛霖覺醒？ 本獨立單元是對台鋼雄鷹的各種新聞及戰況以球迷視角觀察製作的節目；內容除了與掰咖老師合作的賽事回顧，還有其他場外活動、戰績與啦啦隊的相關話題。除了固定的內容之外，也會有鷹鷹去採訪，訪問幕後鷹雄與球迷；以及鷹鷹來講古，講述高雄棒球歷史的考古解析。 這是一個主要聊台灣棒球的Podcast節目，我們沒有精闢的解說，也沒有專業的數據，就是幾個愛棒球的大叔和聽眾們一同喇賽、一同嘴砲~~ 大家可以在相關的 Podcast APP 收聽我們的節目，希望大家可以介紹給喜愛棒球的朋友們。 如果喜歡我們的節目，也希望大家可以在 Apple Podcast 專區給我們五顆星。 有興趣合作的廠商歡迎私訊或email聊聊 email：baseballuncle543@outlook.com IG：baseballuncle543 FB：大叔野球543 －－－－以下訊息由 SoundOn 動態廣告贊助商提供－－－－ 三得利頂級琴酒「六ROKU GIN」200ml 輕巧包裝，在 7-ELEVEN 與全家都買得到！ 隨時隨地享受優雅風味：https://sofm.pse.is/7ksuud -- ✨宏匯廣場 歡慶璀璨女王節✨

謙信著作：歷史偵探武田謙信，共十七集已經完結，在Readmoo kobo 都已經發售，google、amazon 與Bookwalker書店也將上架。 業務合作請洽：japantraveler1@gmail.com athrunzhung@gmail.com 1923年11月8日，慕尼黑的啤酒館，這個當時看似平凡的場所，卻成為了歷史的分水嶺。阿道夫·希特勒，當時僅僅是納粹黨的領袖之一，帶領著一群充滿激情的追隨者，發起了一場名為「啤酒館政變」的行動，企圖推翻當時的魏瑪共和國政府，並建立他心目中的新秩序。這場政變的失敗並沒有結束希特勒的政治生涯，反而成為了他日後崛起的起點，對世界歷史的影響深遠。 1920年代初期的德國處於一個極度動蕩的時期。第一次世界大戰結束後，德國戰敗，根據《凡爾賽條約》，不得不接受一系列苛刻的條件。德國不僅失去了大量領土和資源，還需要支付巨額賠款，這對其經濟造成了極大打擊。隨著賠款的支付，德國的經濟瀕臨崩潰，通貨膨脹達到了前所未有的程度，錢幣的價值急劇下降，民眾的積蓄化為泡影，甚至基本的生活必需品也變得短缺。這一切讓人民對魏瑪共和國政府的無能感到絕望，對未來充滿了不安。 fb專頁：https://www.facebook.com/historysquare/ FB社團：https://www.facebook.com/groups/873307933055348 Podcast : http://kshin.co​ Youtube:https://www.youtube.com/watch?v=C2S-492vfSw&list=PLolto1Euzd4XcbP9oX9JXI3wOlrovdgcC twitter:@alexzhung 電子書著作 Amazon : https://reurl.cc/g8lprR​ Readmoo ：https://reurl.cc/jqpYmm​ Kobo : https://reurl.cc/GdDLgW​ Google : https://reurl.cc/9ZyLyn​ －－－－以下訊息由 SoundOn 動態廣告贊助商提供－－－－ ✨ 富國島，這樣慢慢的就很好！ ✈️ 星宇航空直飛富國島x最美JW萬豪酒店，

欢迎收听雪球出品的财经有深度，雪球，国内领先的集投资交流交易一体的综合财富管理平台，聪明的投资者都在这里。今天分享的内容叫京东集团与美团外卖大战分析及投资展望，来自KAIZEN投资之道。2025年，京东以“品质外卖+低佣金+物流协同”策略高调进军外卖市场，与占据70%份额的美团展开正面交锋。这场战役不仅涉及用户补贴、商家争夺与运力比拼，更是即时零售基础设施与生态协同能力的终极对决。以下从竞争格局、核心竞争力、估值及后市投资价值展开分析。竞争现状与策略对比1. 京东的进攻逻辑一方面，差异化定位：主打“品质堂食外卖”，以连锁品牌商家（如瑞幸、海底捞）为核心，通过“0佣金初期政策+长期5%低费率”吸引优质供给，并依托达达130万骑手和智能调度系统实现30分钟送达。另一方面，物流协同：利用京东物流午间运力闲置（波谷利用率38%），通过外卖订单摊薄边际成本，同时以“外卖赠PLUS会员”反哺电商用户黏性。再者，数据整合：打通外卖消费与3C家电购买行为，探索跨场景精准营销（如“买空气炸锅用户减少炸鸡订单”）。2. 美团的防守策略一方面，护城河加固：凭借680万活跃骑手、5.82亿年交易用户及超脑算法调度系统，强化履约效率；推出“钻石商家计划”降低KA客户抽成至18%，并通过“二选一”协议限制商家多平台运营。另一方面，即时零售扩张：美团闪购日均单量近1000万单，覆盖全品类，2024年已实现微利，形成“高频外卖+低频闪购”的流量闭环。再者，成本控制：通过无人配送试点（如无人机）及算法优化，应对骑手社保成本上升（2025Q2起缴纳），预计运营效率提升可覆盖新增支出。核心竞争力与护城河1.美团 ：首先，强大的即时配送网络 ：拥有 745 万骑手，日均处理 8000 万单，30 分钟送达率达 98%，其闪电仓的前置仓网络深入社区末梢，生鲜损耗率仅 0.3%，能够高效满足用户的即时需求，形成了强大的物流配送优势。其次，庞大的用户和商户基础 ：依托美团 APP 日均 3 亿活跃用户，以及 800 万中小商家的入驻，形成了用户习惯和价格敏感型消费的强锁定效应，通过 “高频打低频” 的策略，实现了业务的协同发展。再者，技术与数据优势 ：凭借 “超脑调度系统” 优化配送路径，动态平衡骑手安全与时效，提升了运营效率。同时，积累了大量的用户消费数据和商家数据，能够实现精准营销和个性化推荐。2.京东 ：首先，卓越的供应链管理能力 ：作为自营电商巨头，京东拥有完善的供应链体系，能够实现从采购、仓储、物流到配送的全流程控制，保障商品的品质和供应的稳定性。通过将家电等品类的配送时效压缩至30 分钟，展示了其供应链的强大竞争力。其次，高品质服务与品牌形象 ：京东以品质和服务著称，在用户心中树立了良好的品牌形象。其推出的 0 佣金吸引海底捞等连锁品牌、骑手五险一金等举措，不仅提升了平台的吸引力，也体现了其对品质和服务的重视，有助于增强用户对平台的信任和认可。再者，强大的电商平台协同效应 ：京东集团的电商资源为外卖业务提供了有力的支持，实现了从线上购物到即时配送的无缝衔接，拓展了用户的消费场景。同时，达达秒送的配送网络也为外卖业务提供了坚实的物流保障。后市投资价值分析1.美团 ：虽然面临着京东等竞争对手的挑战，但其在即时零售和外卖领域的领先地位短期内难以撼动。其强大的配送网络、庞大的用户和商户基础以及丰富的运营经验，构成了深厚的竞争壁垒。随着消费市场的复苏和外卖行业的持续增长，美团有望继续保持稳定的业绩增长，为投资者带来较为可观的长期回报。2.京东 ：京东的外卖业务虽然起步较晚，但凭借其强大的供应链管理能力和品牌优势，有望在外卖市场中占据一席之地。其差异化的发展战略，满足了部分用户对高品质外卖和即时配送的需求，具有较大的发展潜力。此外，京东在电商领域的稳定增长也为外卖业务的发展提供了有力支撑，其多元化的业务布局有助于降低单一业务的风险，从长期来看，具有较高的投资价值。总结京东与美团的竞争本质是“基础设施效率战”与“生态协同战”。美团凭借其强大的即时配送网络、庞大的用户和商户基础以及丰富的运营经验，在短期内仍将占据主导地位；而京东则以卓越的供应链管理能力、高品质服务与品牌形象以及强大的电商平台协同效应为依托，有望在外卖市场中逐步扩大份额。投资者在选择投资标的时，应综合考虑自身风险承受能力、投资目标以及市场环境等因素，对美团和京东的投资价值进行全面评估，以做出合理的投资决策。最后我是持有美团，也坚定看多后市。此时此刻奉上苏轼的《王复秀才所居双桧二首·其一》：“凛凛相对敢相欺，直干凌云未要奇。”

今天是寶博自己說的時間，要再來聊聊最近科技圈有什麼新進展？有什麼值得關注的議題呢？ 今天會聊到的新聞包括： 華為新AI晶片豪言超車輝達，黃仁勳該擔心嗎？ ChatGPT升級購物搜尋功能、免費就能用！ 美國亞利桑那州通過比特幣儲備法案！ Amazon 首波 Project Kuiper 衛星終於升空！ 馬上就一起來關注這陣子世界發生的變化吧！ - - - - - -- - - - - - 【寶博朋友說千萬粉絲專屬社群頻道 Discord 開張啦

你不理財，財不理你！想學理財，玉山罩你！ 玉山銀行全新Podcast節目《玉山學堂》 帶你深入淺出掌握每週市場脈動！ 還有知名主持人蔡尚樺領銜的跨世代對談， 從不同的角度打好理財基本功！ 現在就點擊連結收聽

Phoebe and Randy's meet‑cute at the gas station morphed into a mid‑40s tag‑team battle with blood sugars: hers since age 12, his brand‑new after pancreatic cancer left him with type 3C diabetes. Tandem Mobi ** twiist AID System Free Juicebox Community (non Facebook) JUICE CRUISE 2025 Blue Circle Health Eversense CGM Medtronic Diabetes Drink AG1.com/Juicebox Use code JUICEBOX to save 40% at Cozy Earth  CONTOUR NextGen smart meter and CONTOUR DIABETES app Dexcom G7 Go tubeless with Omnipod 5 or Omnipod DASH * Get your supplies from US MED  or call 888-721-1514 Touched By Type 1 Take the T1DExchange survey Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! *The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.  ** t:slim X2 or Tandem Mobi w/ Control-IQ+ technology (7.9 or newer). RX ONLY. Indicated for patients with type 1 diabetes, 2 years and older. BOXED WARNING:Control-IQ+ technology should not be used by people under age 2, or who use less than 5 units of insulin/day, or who weigh less than 20 lbs. Safety info: tandemdiabetes.com/safetyinfo Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!

The most amazing object visible through a small telescope doesn’t look all that remarkable. In fact, it looks like a faint star. Yet that point of light packs the power of 10 trillion Suns – the power of a quasar. 3C 273 is the first quasar ever discovered. When astronomers first saw it, they thought it was just another star. It looks like a star, and its main ingredient is like a star’s as well. But when they measured its distance, they were astonished: 3C 273 was two and a half billion light-years away. That meant it couldn’t be a star at all. Instead, they classified it as a quasi-stellar object – a quasar. Astronomers eventually figured out that it’s powered by a black hole at the heart of a giant galaxy. The black hole is about 900 million times the mass of the Sun. Its enormous gravity pulls in huge amounts of gas and dust, and maybe some stars. That material forms a spinning disk around the black hole. The disk is heated to millions of degrees, so it shines brilliantly – bright enough to see from two and a half billion light-years away. 3C 273 is in Virgo. The constellation’s brightest star, Spica, is low in the southeast at nightfall. The quasar stands high above it, about a third of the way up the sky. Despite its great power, it’s too faint to see with the eye alone. But a telescope reveals this deceptive wonder – a monster masquerading as a star. Script by Damond Benningfield